Hospitals have a problem.
Not the hardware problem. We have machines that can measure brain lesions down to the micrometer. Cortechs.ai does this with its NeuroQuant MS software. Viz.ai agrees.
The problem is attention.
Doctors are buried in static reports sitting inside PACS archives, waiting to be clicked on if they ever remember. That distinction matters because an algorithm sitting alone is just noise.
So on July 9, these two announced a partnership. It starts with Multiple Sclerosis which affects more than 1.8 million humans globally according to the WHO but it aims for much more.
Here is how it works. The patient gets an MRI. Cortechs processes the data tracking lesion burden and brain volumes. Viz.ai shoves that information directly into the care coordination dashboard the clinical team is already looking at. No separate report to hunt down. Just data right where the decisions happen.
Does it matter?
Yes.
MS is notoriously difficult to monitor consistently. Dr. Tim Showalter who leads the medical side at Viz told me that lesion changes can be subtle and subjective visual reads make reliable tracking nearly impossible. You might miss an enlarging lesion indicating inflammation or a slight shrink in volume hinting at neurodegeneration.
“Quantitative analysis does not replace theradiologist’s read it adds an objective reproducible layer of decision support.”
That is the key point.
It is not a robot replacing the human. It is a better tool for the human.
But this deal also shows us Viz’s real game plan. Instead of building every single disease tool themselves they are acting as the pipe. They have roughly 2000 U.S. hospital customers already using their infrastructure.
Cortechs brings the brain math. Viz brings the road the car drives on.
Kyle Frye at Cortechs puts it simply: he wants quantitative imaging to be an active part of care delivery.
Think about the outcome. Earlier diagnosis? Maybe. Faster treatment initiation? Likely.
Will it change anything for the patient though?
Faster delivery of data is useless if the doctor ignores it. The metrics need to prove better clinical decisions and actual improvements in disease progression. If not then we have built a very expensive speed bump.
Showalter thinks bigger. He calls imaging “the starting point not the ceiling.” He sees other biomarkers joining the parade as evidence matures.
Guidelines shift when tools get easy enough.
The workflow will change because the data arrives in it.
